Measurement of atrophy in multiple sclerosis: Pathological basis, methodological aspects and clinical relevance

Brain

Volumn 125, Issue 8, 2002, Pages 1676-1695

  Miller, David H ^a   Barkhof, Frederik ^c   Frank, Joseph A ^d   Parker, Geoffrey J M ^b   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Atrophy; MRI; Multiple sclerosis

Indexed keywords

BRAIN ATROPHY; CELL PROLIFERATION; GLIOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MEASUREMENT; METHODOLOGY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMYELINIZATION; REVIEW; RISK BENEFIT ANALYSIS; TUMOR VOLUME;

EID: 0036342788     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf177     Document Type: Review

References (103)

1. Voxel-based morphometry - The methods
2. Volumetric analysis of white matter, gray matter, and CSF using fractional volume analysis
3. A dual approach for minimizing false lesion classifications on magnetic resonance images
4. Extensive cortical demyelination in multiple sclerosis brains
5. Detection of ventricular enlargement in patients at the earliest clinical stage of MS
6. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis
7. Blood-brain-barrier damage in multiple sclerosis. Supravital test observations
8. Cognitive function in primary progressive and transitional progressive multiple sclerosis. A controlled study with MRI correlates
9. Histologie de la sclerose en plaques
10. Brain atrophy in clinically early relapsing remitting multiple sclerosis
11. Quantitative cerebral anatomy of the aging human brain: A cross-sectional study using magnetic resonance imaging
12. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
13. Relation of cerebral atrophy in multiple sclerosis to severity of disease and axonal injury
14. Automated estimation of brain volume in multiple sclerosis with BICCR
15. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study
16. A B-spline active surface method for segmentation of the optic nerve
17. Quantification of spinal cord atrophy via an active surface model
18. Normal brain development and aging: Quantitative analysis at in vivo MR imaging in healthy volunteers
19. Sex differences in aging of the human frontal and temporal lobes
20. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the development of multiple sclerosis
21. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images
22. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis
23. Immunoglobulin-containing cells in multiple sclerosis plaques
24. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis
25. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis
26. Axonal damage in acute multiple sclerosis lesions
27. A spinal cord MRI study of benign and secondary progressive multiple sclerosis
28. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis
29. Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis
30. Whole brain volume changes in patients with progressive MS treated with cladribine
31. Brain volume changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis: Results from the ETOMS study
32. Knowledge-based 3D segmentation of the brain in MR images for quantitative multiple sclerosis lesion tracking
33. Usefulness of brain parenchymal fraction for predicting multiple sclerosis disease progression
34. Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients
35. Progressive cerebral atrophy in MS. A serial study using registered, volumetric MRI
36. The boundary shift integral: An accurate and robust measure of cerebral volume changes from registered repeat MRI
37. Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images
38. Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders
39. Spinal cord axonal loss in multiple sclerosis: A post-mortem study
40. MRI brain volume changes in relapsing remitting multiple sclerosis patients treated with interferon beta-1a
41. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
42. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment
43. An image-processing system for qualitative and quantitative volumetric analysis of brain images
44. Gender differences in age effect on brain atrophy measured by magnetic resonance imaging
45. Quantitative follow-up of patients with multiple sclerosis using MRI: Reproducibility
46. Variability of brain atrophy estimates in multiple sclerosis
47. White matter abnormalities in mobility-impaired older persons
48. Continuing optic nerve atrophy following optic neuritis: A serial MRI study using a short echo fast-flair sequence
49. Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence
50. Quantitative brain volumetric analysis from patients with multiple sclerosis: A follow-up study
51. MRI cerebral atrophy in relapsing-remitting MS: Results from the PRISMS trial
52. Optimizing the association between disability and biological markers in MS
53. Neuroprotective treatment in primary progressive MS: A phase I/II study with riluzole
54. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis
55. Cortical lesions in multiple sclerosis
56. Quantitative follow-up of patients with multiple sclerosis using MRI: Technical aspects
57. Histopathology and bloodcerebrospinal fluid barrier in multiple sclerosis
58. Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: The role of quality assurance
59. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis
60. Estimating cerebral atrophy in ms patients from various MR pulse sequences
61. 1-weighted volume MRI data
62. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis
63. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression
64. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study
65. Axonal changes in chronic demyelinated cervical spinal cord plaques
66. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms
67. Correction for head size in brain-imaging measurements
68. The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
69. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
70. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
71. Brain atrophy in relapsing-remitting multiple sclerosis: Relationship with 'black holes', disease duration and clinical disability
72. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood
73. Adaptive fuzzy segmentation of magnetic resonance images
74. An adaptive fuzzy C-means algorithm for image segmentation in the presence of intensity inhomogeneities
75. DispImage: A display and analysis tool for medical images
76. Effect of intravenous methylprednisolone on MRI measures of disease activity in RRMS patients before and after interferon beta-1b
77. Cladribine and progressive MS. Clinical and MRI outcomes of a multicenter controlled trial
78. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis
79. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
80. Use of the brain parencyhmal fraction to measure whole brain atrophy in relapsing-remitting MS
81. 1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study
82. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS
83. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: A preliminary study
84. A longitudinal study of brain atrophy in relapsing multiple sclerosis
85. A nonparametric method for automatic correction of intensity nonuniformity in MRI data
86. Normalized accurate measurement of longitudinal brain change
87. Spinal cord atrophy and disability in MS. A longitudinal study
88. One year follow up study of primary and transitional progressive multiple sclerosis
89. Macrophage function during Wallerian degeneration of rat optic nerve: Clearance of degenerating myelin and Ia expression
90. Some spaces and barriers in postmortem multiple sclerosis
91. Axonal transection in the lesions of multiple sclerosis
92. Exploratory treatment trials in multiple sclerosis using MRI: Sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups
93. Multiple sclerosis lesion quantification using fuzzyconnectedness principles
94. 1-weighted spin-echo MRI in multiple sclerosis
95. Haemodialysis and cerebral oedema
96. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: A functional magnetic resonance imaging study
97. Normalization of cerebral volumes by use of intracranial volume: Implications for longitudinal quantitative MR imaging
98. Linomide in relapsing and secondary progressive MS: Part II: MRI results
99. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
100. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm
101. Brain segmentation and white matter lesion detection in MR images
102. Automatic quantification of multiple sclerosis lesion volume using stereotaxic space